Incyte (NasdaqGS:INCY) agreed to acquire Vega Therapeutics in an all cash deal valued at up to US$2b. The transaction brings Vega's late stage subcutaneous antibody therapy candidate, VGA039, for von
By Karen Roman Imviva Biotech said it is presenting two findings associated with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at the European Hematology Associatio
Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.8% in the morning session after several analyst firms raised their price targets following its acquisition of Vega Therape
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, h
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.
View interactive chart, options flow, and AI analysis for INCY on Zorveq Finance.
Open INCY Chart & Analysis →